Experts suggest repurposing licensed drugs such as antibiotics, antivirals, and anti-inflammatories to address dementia, which is projected to affect 153 million people globally by 2050. With new drug development moving slowly, using already approved medications could allow for quicker clinical trials. Research from the University of Cambridge indicates some drugs may lower dementia risk, and while several candidates merit deeper exploration, findings showed inconsistency across studies—highlighting a need for further investigation into the role of infections and inflammation in dementia development.
The urgency for new dementia treatments is paramount, with experts advocating for repurposing existing licensed drugs to expedite trials and patient access.
The analysis of over one million dementia cases revealed that while some drugs linked to dementia risk were identified, inconsistencies remain in the research.
Collection
[
|
...
]